BioNTech CEO sells 61,000 shares under plan

Posted by Chris Copeland on Sep 28th, 2026

What happened

BioNTech SE (NASDAQ: BNTX) filed a Form 4 on 09/28/2026 reporting Chief Executive Officer and 10% owner Ugur Sahin's sales of Ordinary Shares. He sold 27,000 shares on 09/25/2026 at $98.6882 and 34,000 shares on 09/28/2026 at $98.4682, leaving 280,209 shares after the second sale. The form says the trades were made under a Rule 10b5-1 trading plan established on June 3, 2026.

It also lists 39,218,111 ordinary shares held indirectly through Medine GmbH, and says 106,721 of those are held for the benefit of an individual under a trust arrangement. Sahin is the sole shareholder of Medine GmbH, and the reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.

Key numbers

Metric	Latest	Source
Shares sold	61,000 shares	SEC Form 4
Total sale value	about $6.01 million	SEC Form 4
Sale price range	from $98.47 to $98.69 per share	SEC Form 4
Shares held after sale	280,209 shares	SEC Form 4
Shares sold as share of pre-trade holding	17.9%	Calculated from SEC Form 4

Why it matters

The 61,000-share sale was about $6.01 million in total, and the shares sold were about 17.9% of the holding before the first sale. Sahin still held 280,209 shares after the second trade, so the filing shows a reduction rather than an exit. That indirect block is larger than the 61,000 shares sold, so this filing is a direct ownership trim, not a full retreat from the stock.

The counterargument is that the filing itself marks the sales as Rule 10b5-1 trades, which can make the selling look preplanned instead of a fresh negative view. OptimistFi's case is that BioNTech is a cash-rich COVID-windfall reinvestment story whose stock depends on its mRNA and immunotherapy platform becoming a durable non-COVID oncology business. This filing is mixed because it changes insider ownership, but it does not show operating progress.

What's next

The plan date on the filing is June 3, 2026. Later sales reported under that plan would deepen the trim, while no further sales would leave this as a single planned reduction. The current post-sale holding is 280,209 shares, which gives investors a clean baseline for later ownership changes.

Sources

SEC Form 4 — Form 4 filed 2026-09-28 reporting Ugur Sahin's sales of Ordinary Shares under a Rule 10b5-1 trading plan.

Read the full OptimistFi thesis on BioNTech SE: https://optimistfi.com/stocks/BNTX

See what would break the BioNTech SE thesis and track it live on the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

The full BioNTech SE investment case, its status and the next test to watch live on the BioNTech SE thesis page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.